JP6192741B2 - 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 - Google Patents

新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 Download PDF

Info

Publication number
JP6192741B2
JP6192741B2 JP2015555474A JP2015555474A JP6192741B2 JP 6192741 B2 JP6192741 B2 JP 6192741B2 JP 2015555474 A JP2015555474 A JP 2015555474A JP 2015555474 A JP2015555474 A JP 2015555474A JP 6192741 B2 JP6192741 B2 JP 6192741B2
Authority
JP
Japan
Prior art keywords
group
ethynyl
amino
methyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015555474A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2015199136A1 (ja
Inventor
尊志 水谷
尊志 水谷
千穂子 吉村
千穂子 吉村
ひとみ 近藤
ひとみ 近藤
誠 北出
誠 北出
大久保　秀一
秀一 大久保
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2015199136A1 publication Critical patent/JPWO2015199136A1/ja
Application granted granted Critical
Publication of JP6192741B2 publication Critical patent/JP6192741B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015555474A 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 Expired - Fee Related JP6192741B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2014129740 2014-06-24
JP2015024785 2015-02-10
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤

Publications (2)

Publication Number Publication Date
JPWO2015199136A1 JPWO2015199136A1 (ja) 2017-04-27
JP6192741B2 true JP6192741B2 (ja) 2017-09-06

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555474A Expired - Fee Related JP6192741B2 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤

Country Status (21)

Country Link
US (2) US9963456B2 (enExample)
EP (1) EP3103802B1 (enExample)
JP (1) JP6192741B2 (enExample)
KR (1) KR101947289B1 (enExample)
CN (1) CN106661031B (enExample)
AU (1) AU2015281155B9 (enExample)
BR (1) BR112016025835B1 (enExample)
CA (1) CA2946833C (enExample)
DK (1) DK3103802T3 (enExample)
ES (1) ES2656772T3 (enExample)
HU (1) HUE037266T2 (enExample)
MX (1) MX2016015015A (enExample)
MY (1) MY183327A (enExample)
NO (1) NO3103802T3 (enExample)
PH (1) PH12016502130B1 (enExample)
PL (1) PL3103802T3 (enExample)
PT (1) PT3103802T (enExample)
RU (1) RU2658008C2 (enExample)
SG (1) SG11201608441YA (enExample)
TW (1) TWI605048B (enExample)
WO (1) WO2015199136A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017111074A1 (ja) * 2015-12-22 2018-05-10 大鵬薬品工業株式会社 ピロロピリミジン化合物による抗腫瘍効果増強剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
WO2018110591A1 (ja) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 抗ウイルス活性を有する２'－デオキシ－７－デアザプリンヌクレオシド誘導体
TWI802635B (zh) * 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN113382754A (zh) * 2018-07-13 2021-09-10 Il-2Rx公司 治疗癌症和免疫病症的化合物、组合物、方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1848718T1 (sl) * 2005-02-04 2012-12-31 Millennium Pharmaceuticals, Inc. Inhibitorji E1 aktivacijskih enzimov
US7989430B2 (en) 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
ES2593433T3 (es) 2006-02-02 2016-12-09 Millennium Pharmaceuticals, Inc. Inhibidores de las enzimas activadoras E1
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
CN103298817A (zh) 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
EP2738873A4 (en) * 2011-07-29 2015-04-01 Kuang Chi Innovative Tech Ltd ARTIFICIAL COMPOSITE MATERIAL AND ANTENNA PRODUCED FROM ARTIFICIAL COMPOSITE MATERIAL
CN103958512B (zh) * 2012-01-19 2016-01-20 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017111074A1 (ja) * 2015-12-22 2018-05-10 大鵬薬品工業株式会社 ピロロピリミジン化合物による抗腫瘍効果増強剤

Also Published As

Publication number Publication date
CN106661031A (zh) 2017-05-10
KR20170016510A (ko) 2017-02-13
PT3103802T (pt) 2017-12-11
KR101947289B1 (ko) 2019-02-12
DK3103802T3 (en) 2017-12-11
US9963456B2 (en) 2018-05-08
PH12016502130A1 (en) 2016-12-19
CN106661031B (zh) 2019-07-23
US20170066772A1 (en) 2017-03-09
PL3103802T3 (pl) 2018-02-28
TW201625629A (zh) 2016-07-16
SG11201608441YA (en) 2016-11-29
MY183327A (en) 2021-02-18
HUE037266T2 (hu) 2018-08-28
JPWO2015199136A1 (ja) 2017-04-27
CA2946833A1 (en) 2015-12-30
PH12016502130B1 (en) 2016-12-19
WO2015199136A1 (ja) 2015-12-30
US20180162864A1 (en) 2018-06-14
EP3103802A1 (en) 2016-12-14
EP3103802B1 (en) 2017-11-08
BR112016025835B1 (pt) 2022-09-20
US10174040B2 (en) 2019-01-08
RU2658008C2 (ru) 2018-06-19
MX2016015015A (es) 2017-02-27
AU2015281155A1 (en) 2016-11-03
BR112016025835A2 (enExample) 2017-08-15
AU2015281155B2 (en) 2017-07-13
CA2946833C (en) 2019-03-05
RU2016149319A3 (enExample) 2018-06-18
ES2656772T3 (es) 2018-02-28
RU2016149319A (ru) 2018-06-18
EP3103802A4 (en) 2017-03-08
AU2015281155B9 (en) 2017-11-16
TWI605048B (zh) 2017-11-11
NO3103802T3 (enExample) 2018-04-07

Similar Documents

Publication Publication Date Title
JP6437140B2 (ja) ピロロピリミジン化合物による抗腫瘍効果増強剤
JP6192741B2 (ja) 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
JP6001635B2 (ja) ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法
KR20150058257A (ko) 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
US20240150349A1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
EP4667458A1 (en) Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug
CN115403584A (zh) 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CN117858872A (zh) 用于治疗癌症的杂环egfr抑制剂
JP7433463B2 (ja) ピリミジン含有含窒素二環化合物
HK1236948B (zh) 毗咯并嘧啶化合物或其盐、含有其的药物组合物及应用
HK1236948A1 (en) Pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, and applications
US20250326772A1 (en) Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170630

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170808

R150 Certificate of patent or registration of utility model

Ref document number: 6192741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees